Barry Investment Advisors LLC decreased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 4.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 9,818 shares of the biopharmaceutical company’s stock after selling 481 shares during the quarter. Barry Investment Advisors LLC’s holdings in Gilead Sciences were worth $622,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also modified their holdings of GILD. Wealthsource Partners LLC grew its position in shares of Gilead Sciences by 169.3% during the 2nd quarter. Wealthsource Partners LLC now owns 14,279 shares of the biopharmaceutical company’s stock valued at $965,000 after purchasing an additional 8,976 shares in the last quarter. Goodman Financial Corp grew its position in shares of Gilead Sciences by 3.6% during the 2nd quarter. Goodman Financial Corp now owns 91,771 shares of the biopharmaceutical company’s stock valued at $6,200,000 after purchasing an additional 3,216 shares in the last quarter. Hoylecohen LLC grew its position in shares of Gilead Sciences by 0.4% during the 2nd quarter. Hoylecohen LLC now owns 83,965 shares of the biopharmaceutical company’s stock valued at $5,673,000 after purchasing an additional 350 shares in the last quarter. GW Henssler & Associates Ltd. grew its position in shares of Gilead Sciences by 0.9% during the 2nd quarter. GW Henssler & Associates Ltd. now owns 182,157 shares of the biopharmaceutical company’s stock valued at $12,307,000 after purchasing an additional 1,708 shares in the last quarter. Finally, KBC Group NV grew its position in shares of Gilead Sciences by 15.4% during the 2nd quarter. KBC Group NV now owns 415,362 shares of the biopharmaceutical company’s stock valued at $28,062,000 after purchasing an additional 55,323 shares in the last quarter. 79.91% of the stock is currently owned by institutional investors and hedge funds.

Shares of NASDAQ:GILD opened at $65.38 on Friday. Gilead Sciences, Inc. has a 52-week low of $60.32 and a 52-week high of $72.90. The firm has a fifty day moving average of $64.15 and a 200 day moving average of $65.25. The firm has a market capitalization of $82.81 billion, a PE ratio of 10.63, a price-to-earnings-growth ratio of 3.47 and a beta of 1.09. The company has a debt-to-equity ratio of 1.13, a quick ratio of 2.96 and a current ratio of 3.06.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, October 24th. The biopharmaceutical company reported $1.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.74 by $0.01. Gilead Sciences had a net margin of 12.04% and a return on equity of 37.50%. The company had revenue of $5.60 billion during the quarter, compared to analyst estimates of $5.61 billion. During the same period in the previous year, the business earned $1.84 earnings per share. The firm’s quarterly revenue was up .1% compared to the same quarter last year. On average, sell-side analysts forecast that Gilead Sciences, Inc. will post 6.66 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Monday, December 30th. Investors of record on Friday, December 13th will be given a $0.63 dividend. The ex-dividend date of this dividend is Thursday, December 12th. This represents a $2.52 annualized dividend and a yield of 3.85%. Gilead Sciences’s dividend payout ratio (DPR) is presently 40.98%.

GILD has been the subject of a number of recent analyst reports. Mizuho set a $81.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a research report on Tuesday, October 15th. Bank of America initiated coverage on shares of Gilead Sciences in a research report on Wednesday, October 16th. They set a “neutral” rating and a $70.00 price target for the company. Oppenheimer reduced their price target on shares of Gilead Sciences from $85.00 to $80.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Raymond James reduced their price target on shares of Gilead Sciences from $85.00 to $81.00 and set a “strong-buy” rating for the company in a research report on Friday, October 25th. Finally, Citigroup set a $78.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a research report on Wednesday, July 31st. One research analyst has rated the stock with a sell rating, ten have given a hold rating, fourteen have issued a buy rating and two have issued a strong buy rating to the company’s stock. Gilead Sciences currently has a consensus rating of “Buy” and a consensus target price of $79.27.

In other Gilead Sciences news, EVP Brett A. Pletcher sold 608 shares of the business’s stock in a transaction on Monday, August 19th. The shares were sold at an average price of $64.35, for a total value of $39,124.80. Following the completion of the sale, the executive vice president now directly owns 27,198 shares of the company’s stock, valued at $1,750,191.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Brett A. Pletcher sold 5,677 shares of the business’s stock in a transaction on Monday, October 28th. The stock was sold at an average price of $63.31, for a total transaction of $359,410.87. Following the completion of the sale, the executive vice president now directly owns 21,521 shares of the company’s stock, valued at $1,362,494.51. The disclosure for this sale can be found here. Insiders sold 17,288 shares of company stock valued at $1,108,682 over the last quarter. 0.20% of the stock is owned by company insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Recommended Story: Risk Tolerance

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.